Cure of gastric ulcer disease after cure of Helicobacter pylori infection--German Gastric Ulcer Study

Eur J Gastroenterol Hepatol. 1996 Apr;8(4):343-9. doi: 10.1097/00042737-199604000-00011.

Abstract

Background: Helicobacter pylori infection is associated with gastric ulcer disease in about 75% of cases.

Objective: The aim of this study was to determine whether H. pylori eradication reduces gastric ulcer relapse rates.

Design: The study was randomized, controlled, multicentric and investigator blinded, and was conducted at three university hospitals, two teaching hospitals, and by six practising gastroenterologists.

Methods: During a period of 1 year 152 patients with gastric ulcers were randomly assigned to one of two treatment regimens: omeprazole 20 mg daily in the morning for 8 weeks (74 patients), or bismuth subsalicylate 600 mg three times daily for 8 weeks combined with 500 mg amoxicillin twice daily and 1000 mg tinidazole twice daily for the first 10 days (triple therapy) (78 patients). Follow-up examinations were performed 6, 12 and 18 months after treatment and whenever ulcer symptoms occurred.

Results: Of the 152 randomized patients five were excluded because of gastric cancer, 10 missed follow-up examinations and seven receiving triple therapy terminated treatment because of side effects. Of the remaining 130 patients, five of 69 (7.2%) in the omeprazole and six of 61 (9.8%) in the triple group were H. pylori negative. After 8 weeks' therapy, the gastric ulcer was healed in 85.9% (omeprazole) and in 81.8% triple) in H. pylori-positive patients, and in 80% (omeprazole) and 16.7% (triple) in H. pylori-negatives. H. pylori was eradicated in 8.1% of the patients who received omeprazole monotherapy and in 78.2% receiving triple therapy, and in 8.1% and 69.4% in an intention-to-treat analysis. The subsequent relapse rates during a follow-up period of 12 months were 50% in the omeprazole group and 4% in the triple group. Gastric ulcer relapse was observed in 49% of patients who were H. pylori positive and in 2% who were H. pylori negative after treatment.

Conclusion: The data show that the presence of H. pylori is an important predictor of gastric ulcer relapse and that eradication of H. pylori may heal gastric ulcer disease.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Amoxicillin / therapeutic use*
  • Anti-Ulcer Agents / therapeutic use*
  • Biopsy
  • Bismuth / therapeutic use*
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Gastric Mucosa / microbiology
  • Helicobacter Infections / drug therapy*
  • Helicobacter pylori*
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Omeprazole / therapeutic use*
  • Organometallic Compounds / therapeutic use*
  • Penicillins / therapeutic use*
  • Recurrence
  • Salicylates / therapeutic use*
  • Stomach Ulcer / microbiology*
  • Stomach Ulcer / prevention & control
  • Time Factors
  • Tinidazole / therapeutic use*

Substances

  • Anti-Ulcer Agents
  • Organometallic Compounds
  • Penicillins
  • Salicylates
  • Tinidazole
  • bismuth subsalicylate
  • Amoxicillin
  • Omeprazole
  • Bismuth